Skin barrier dysfunction and low antimicrobial peptide expression in cutaneous T-cell lymphoma

H Suga, M Sugaya, T Miyagaki, H Ohmatsu… - Clinical cancer …, 2014 - AACR
H Suga, M Sugaya, T Miyagaki, H Ohmatsu, M Kawaguchi, N Takahashi, H Fujita, Y Asano…
Clinical cancer research, 2014AACR
Purpose: Atopic dermatitis is characterized by decreased expression of filaggrin and loricrin.
Patients with atopic dermatitis often suffer from skin infections, which are also frequently
seen in patients with cutaneous T-cell lymphoma (CTCL). In this study, we aimed to
investigate the skin barrier in CTCL. Experimental Design: We assessed skin moisture and
transepidermal water loss (TEWL) in patients with CTCL. We next examined mRNA
expression levels of filaggrin, loricrin, and antimicrobial peptides (AMP) in skin samples of …
Abstract
Purpose: Atopic dermatitis is characterized by decreased expression of filaggrin and loricrin. Patients with atopic dermatitis often suffer from skin infections, which are also frequently seen in patients with cutaneous T-cell lymphoma (CTCL). In this study, we aimed to investigate the skin barrier in CTCL.
Experimental Design: We assessed skin moisture and transepidermal water loss (TEWL) in patients with CTCL. We next examined mRNA expression levels of filaggrin, loricrin, and antimicrobial peptides (AMP) in skin samples of CTCL, using skin from healthy volunteers and patients with atopic dermatitis or psoriasis as controls. Immunostainings for filaggrin, loricrin, and S100 proteins were also performed.
Results: Lower levels of skin moisture accompanied by higher levels of TEWL were seen in lesional skin of CTCL than in normal skin. CTCL lesional skin contained lower levels of filaggrin and loricrin mRNA than normal skin, which was also true with atopic dermatitis and psoriatic skin. mRNA expression levels of filaggrin in CTCL skin negatively correlated with disease severity markers. Expression levels of AMPs in lesional skin of CTCL and atopic dermatitis were significantly lower than in psoriatic skin. Immunohistochemistry confirmed decreased expression of filaggrin and loricrin in CTCL, atopic dermatitis, and psoriatic skin and enhanced expression of S100 proteins in psoriatic skin.
Conclusions: Our results show that there is barrier dysfunction in CTCL skin, similar to what is seen with atopic dermatitis skin. In addition, low AMP expression in CTCL skin was documented when compared with psoriatic skin, which may explain frequent infections that can occur in patients with CTCL. Clin Cancer Res; 20(16); 4339–48. ©2014 AACR.
AACR